Selected Clinical and Laboratory Features in Subgroups of CD19+ ALL
| Feature . | CD10+34+ . | CD10+34− . | CD10−34+ . | CD10−34− . | P Value . |
|---|---|---|---|---|---|
| No. of patients | 124 | 24 | 43 | 13 | |
| Median age | 34 | 32 | 35 | 48 | .28 |
| (range) | 17-78 | 17-64 | 17-78 | 19-75 | |
| Median WBC count | 12.9 | 8.5 | 26.9 | 11.8 | .04 |
| (range) | 0.3-307 | 0.7-110 | 0.8-251 | 1.7-72 | |
| Response: | |||||
| CR (%) | 105 (85%) | 23 (96%) | 34 (79%) | 11 (85%) | .32 |
| No CR (%) | 19 (15%) | 1 (4%) | 9 (21%) | 2 (15%) | |
| Time to CR: | |||||
| ≤30 d (%) | 75 (71%) | 15 (65%) | 22 (65%) | 9 (82%) | .64 |
| >30 d (%) | 30 (29%) | 8 (35%) | 12 (35%) | 2 (18%) | |
| Median DFS (yr) | 1.9 | >2.3 | 1.1 | >.7 | .24 |
| Median survival (yr) | 2.1 | 3.7 | 1.1 | 1.1 | .20 |
| 3-yr probability of DFS (95% CI) | .34 (.25-.45) | .55 (.33-.75) | .37 (.22-.55) | .55 (.26-.80) | |
| 5-yr probability of DFS (95% CI) | .24 (.11-.45) | .55 (.26-.81) | .27 (.13-.47) | .55 (.21-.85) | |
| 3-yr probability of survival (95% CI) | .40 (.31-.50) | .67 (.45-.83) | .34 (.21-.49) | .43 (.20-.70) | |
| 5-yr probability of survival (95% CI) | .31 (.16-.52) | .48 (.24-.72) | .34 (.18-.54) | .43 (.16-.75) | |
| Ph chromosome: | |||||
| Negative | 35 | 11 | 24 | 7 | .003 |
| Positive6-150 | 34 (49%) | 2 (15%) | 7 (23%) | 0 (0%) |
| Feature . | CD10+34+ . | CD10+34− . | CD10−34+ . | CD10−34− . | P Value . |
|---|---|---|---|---|---|
| No. of patients | 124 | 24 | 43 | 13 | |
| Median age | 34 | 32 | 35 | 48 | .28 |
| (range) | 17-78 | 17-64 | 17-78 | 19-75 | |
| Median WBC count | 12.9 | 8.5 | 26.9 | 11.8 | .04 |
| (range) | 0.3-307 | 0.7-110 | 0.8-251 | 1.7-72 | |
| Response: | |||||
| CR (%) | 105 (85%) | 23 (96%) | 34 (79%) | 11 (85%) | .32 |
| No CR (%) | 19 (15%) | 1 (4%) | 9 (21%) | 2 (15%) | |
| Time to CR: | |||||
| ≤30 d (%) | 75 (71%) | 15 (65%) | 22 (65%) | 9 (82%) | .64 |
| >30 d (%) | 30 (29%) | 8 (35%) | 12 (35%) | 2 (18%) | |
| Median DFS (yr) | 1.9 | >2.3 | 1.1 | >.7 | .24 |
| Median survival (yr) | 2.1 | 3.7 | 1.1 | 1.1 | .20 |
| 3-yr probability of DFS (95% CI) | .34 (.25-.45) | .55 (.33-.75) | .37 (.22-.55) | .55 (.26-.80) | |
| 5-yr probability of DFS (95% CI) | .24 (.11-.45) | .55 (.26-.81) | .27 (.13-.47) | .55 (.21-.85) | |
| 3-yr probability of survival (95% CI) | .40 (.31-.50) | .67 (.45-.83) | .34 (.21-.49) | .43 (.20-.70) | |
| 5-yr probability of survival (95% CI) | .31 (.16-.52) | .48 (.24-.72) | .34 (.18-.54) | .43 (.16-.75) | |
| Ph chromosome: | |||||
| Negative | 35 | 11 | 24 | 7 | .003 |
| Positive6-150 | 34 (49%) | 2 (15%) | 7 (23%) | 0 (0%) |
The P values are based on 3 degrees of freedom tests.
Ph chromosome positive refers to patients that are BCR/ABL+ by molecular assay and/or have a t(9;22) cytogenetic karyotype.